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Introduction
Acinetobacter baumannii is a non-motile, aerobic, Gram-
negative opportunistic pathogen often causing serious, life-
threatening infections found most frequently in healthcare-
associated infections (HAI), including ventilator-associated 
pneumonia (VAP) [1]. Effective treatments for the management 
of invasive A. baumannii infections are significantly limited 
due to high rates of resistance to fluoroquinolones, tigecycline, 
aminoglycosides, and β-lactams including carbapenems [2]. 
This  is  particularly  notable  in  isolates  associated  with 
HAI (up to 63% in one report) [3]. For these reasons, A. 
baumannii has been identified together with other notable 
nosocomial multi-drug resistant (MDR) organisms as an 
ESKAPE pathogen (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pnemoniae, Acinetobacter baumannii, 
Pseduomonas aeruginosa, and Enterobacter species) [4]. 
Due to the continued global rise in A. baumannii resistance, 
in 2013 the Centers for Disease Control and Prevention (CDC) 
declared MDR A. baumannii a serious threat [3]. Carbapenem 
resistance in A. baumannii is independently associated with 
increased hospital mortality and prolonged ICU and hospital 
stays [6,7]. In 2017, the World Health Organization (WHO) 
placed carbapenem-resistant A. baumannii (CRAB) on its 
global priority list as a critical threat to promote and encourage 
the research and development of new antibiotics [5,8].
Currently, there are a limited number of effective therapies 
targeting this highly resistant pathogen [9]. The  polymyxins, 
minocycline,  tigecycline,  amikacin,  and  sulbactam-
containing agents are potential antimicrobial treatment 
options, yet significant limitations exist for each agent. 
These include increasing rates of resistance, inadequate 
in vitro susceptibility testing methods, suboptimal tissue 
concentrations, and toxicity profiles. Emerging treatment 
options include the combination of “older” agents, new 
antibiotics, and novel (non-antibiotic) therapies. It is 
the objective of this review to describe the mechanisms, 
epidemiology, and the current and developing management 
strategies of invasive infections due to MDR A.baumannii.
Mechanisms of Antimicrobial 
Resistance
While definitions vary between sources, the term MDR most 
often refers to in vitro resistance to 3 or more antimicrobial 
classes, while extensively drug-resistant (XDR) is generally 
used to describe resistance that excludes most standard 
antimicrobial classes [10]. While MDR isolates may be 
susceptible to a carbapenem in vitro, XDR A. baumannii is most 
often carbapenem-resistant. For A. baumannii, pan-resistance 
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(PDR) describe isolates with in vitro resistance to all β-lactams 
(including carbapenems), aminoglycosides, fluoroquinolones, 
and polymyxins [10].
While not the most common of the ESKAPE pathogens, A. 
baumannii is considered one of the most serious threats to 
healthcare due to its extraordinary ability to quickly adapt 
to selective environmental pressures (notably antibiotics) 
[4,11,12]. Mechanisms of drug resistance are diverse and 
include β-lactamase production, multidrug efflux pumps, 
aminoglycoside-modifying enzymes, permeability defects, and 
alteration in target binding sites [13,14]. These mechanisms 
often work in tandem to convey resistance to multiple antibiotic 
classes. Resistance may be a result of both vertical transfer 
and its natural ability to integrate exogenous DNA into its own 
genome [11].
Production of β-lactamases is generally considered to be 
the most prevalent mechanism of antibiotic resistance in A. 
baumannii. Each of the Ambler classes of β-lactamases (Class 
A-D) have been isolated from A. baumannii, conferring 
resistance to many commonly used β-lactam antibiotics [11]. In 
addition to the intrinsic Class C β-lactamases, other serine-
dependent β-lactamases include Class A β-lactamases (TEM, 
SHV, CTX-M, KPC, and others) that hydrolyze penicillin and 
cephalosporins and Class D β-lactamases, oxacillinases (OXA). 
Class D β-lactamases are the most prominent β-lactamase 
conferring resistance to carbapenems via enzymatic degradation 
with MDR isolates often containing more than one oxacillinase. 
Class B β-lactamases, or metallo-β-lactamases (MBL), are 
the broadest spectrum β-lactamase that hydrolyze almost all 
β-lactams, including carbapenems. A number of MBL enzymes 
have been recognized in A. baumannii including IMP, VIM, and 
NDM [13,15].
In addition to β-lactamase production, other well-described 
mechanisms contributing to MDR isolates include efflux 
pumps, decreased permeability of the cell wall, and alterations 
in target sites. Two efflux pumps, tet(A) and tet(B), are 
tetracycline specific efflux pumps that confer resistance to 
most tetracyclines, with the exception of tigecycline [16]. 
Tet(A) confers resistance to tetracycline, while tet(B) is highly 
suggestive for minocycline resistance [11,17,18]. Multidrug 
efflux pumps, such as AdeFGH and AdeABC, increase resistance 
to many antibiotics, including carbapenems, tetracyclines, 
and even tigecycline [11,15]. Interestingly, subinhibitory 
concentrations of antibiotics due to low-dose treatment can 
induce upregulation of the AdeFGH efflux pump, thereby 
increasing biofilm formation [19]. The AdeABC efflux pump is 
the most well-described multidrug efflux pump in A. baumannii 
and effects β-lactams, aminoglycosides, tetracyclines, 
fluoroquinolones, and others [11]. The AdeABC efflux pump 
can also be upregulated when exposed to subinhibitory 
concentrations. This mechanism may be most notable when 
exposing A. baumannii to subinhibitory concentrations of 
tigecycline, such as for treatment of bacteremia, as increased 
minimum inhibitory concentrations (MICs) have been 
found in vitro and likely contribute to poor clinical outcomes 
[20]. A reduction in porin channels affecting membrane 
permeability of many antibiotics have also been reported, while 
a downregulation or alteration in lipopolysaccharides found 
on the outer membrane of A. baumannii increases resistance 
to colistin [21]. Finally, overexpression or alteration of target 
sites via penicillin-binding protein (PBP) result  in decreased 
susceptibility of  carbapenems, while the presence of GyrA 
or aminoglycoside-modifying enzymes are key contributors to 
quinolone and aminoglycoside resistance, respectively [15].
Epidemology of MDR and XDR A. 
baumannii Infections
With the capabilities of forming biofilm and its propensity to 
survive harsh, dry conditions, A. baumannii is a significant 
hospital-acquired pathogen, particularly found in the 
intensive care units (ICU) [22]. Risk factors for Acinetobacter 
spp acquisition include receipt of broad-spectrum antibiotics 
(specifically later generation cephalosporins), receipt and 
duration of mechanical ventilation, ICU admission and duration 
of stay, invasive procedures or devices, total parenteral nutrition, 
and exposure to contaminated sources [1]. While most notable 
for causing respiratory tract infections (including VAP), it has 
also been reported to cause bloodstream infections (BSI), wound 
or acute bacterial skin and skin structure infections (ABSSSI), 
complicated urinary tract infections (cUTI), complicated intra-
abdominal infections (cIAI), and meningitis [1]. A. baumannii 
has the propensity for biofilm formation, making it particularly 
difficult to eradicate in certain conditions (notably on blood and 
urinary catheters and endotracheal tubes) [23]. According to 
the National Healthcare Safety Network (NHSN), A. baumannii 
is the fifth most common VAP pathogen, accounting for 6.1% to 
7.5% of all cases [24,25]. Despite only 2% of HAIs are caused 
by Acinetobacter spp., crude mortality in patients with A. 
baumannii infections can be as high as 75% [3,26].
Antimicrobial resistance in A. baumannii has demonstrated 
notable increases in the last several years. For example, the 
Meropenem Yearly Susceptibility Test Information Collection 
Program demonstrated a 61% increase in meropenem resistance 
over a 10-year period (1999-2008). Tobramycin maintained 
the highest susceptibility rate over this period (59.1%) followed 
by meropenem (45.7%), levofloxacin (33.9%) and ceftazidime 
(31.5%) [2]. In a more recent global pooled prevalence study 
assessing resistance in A. baumannii infections from countries 
participating in the Organization for Economic Cooperation and 
Development, a 55.7% meropenem resistance rate was reported 
from 2006-2016. Meropenem resistance increased dramatically 
from 25.7% in the years 2000 to 2005 compared to 55.6% from 
2006 to 2010 and increased further to 70.1% from 2011 to 
2016. Amikacin resistance increased from 38.2% to 43.6% to 
66.6% over the same period, respectively [27].
Limitations of Established Monotherapy 
Treatments for MDR A. baumannii
Polymyxins
Discovered over 70 years ago, use of the polymyxins (polymyxin 
B and colistin) have reemerged due to the rise in MDR Gram-
negative pathogens, including (but not limited to) CRAB. Use of 
polymyxins is generally limited by a narrow therapeutic window, 
with the most significant  (often  treatment-limiting)  adverse 
effects  of  nephrotoxicity  and  neurotoxicity (occurring in 
6% to 55% and 7% to 27% of patients, respectively) [28,29]. 
Polymyxins are further restricted from widespread use in 
invasive infections due to lack of optimal exposure targets in 
critically ill patients and lack of reliable in vitro colistin testing 
[30].
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Since colistin is administered as the inactive prodrug 
formulation, colistin methanesulfonate (CMS), some 
hypothesize that the delayed conversion to the active 
form may result in reduced bacterial killing and promote 
the development of treatment-emergent resistance or in 
subsequent A. baumannii isolates [31-33]. When colistin MICs 
to A. baumannii approach  the  susceptible breakpoint (< 2 μg/
mL, see Table 2), attaining adequate serum concentrations 
in subjects with normal renal function is reported in only 30-
40% of patients receiving loading doses and at the maximum 
recommended maintenance dose  (capped  due  to  increased 
toxicity risks) [30,34]. Likewise, at the highest recommended 
doses, polymyxin B is not consistently effective at achieving 
optimal respiratory tract concentrations [30]. Furthermore, 
rates of colistin resistance in respiratory isolates are increasing 
[12,35]. The most concerning report of colistin resistance is 
from a collection of VAP isolates from Europe. These isolates 
demonstrated a 47.7% resistance rate with an MIC50/90 
of 2 μg/mL and 256 μg/mL, respectively [12]. Previous 
treatment with colistin is regarded as a significant risk factor 
for the development of colistin heteroresistance, with colistin 
resistance being associated with poor clinical outcomes [36-38]. 
This is most evident in a report of 19 patients infected with a 
colistin-susceptible isolate and treated with intravenous CMS, 
inhaled CMS, or both [37]. Colistin resistance was isolated in 
all 19 patients after a median interval of 20 days. Of note, the 
authors do not comment on the dosing of CMS. Retrospective 
evaluations of colistin monotherapy versus a monotherapy 
comparator agent (ampicillin/sulbactam) in the treatment 
of mixed CRAB infections demonstrated increased 30-day 
mortality and mortality during therapy in the colistin cohorts 
[39,40]. In a prospective evaluation of 28 MDR A. baumannii 
VAP patients treated with colistin or imipenem-cilastatin, 
clinical efficacy was similar among cohorts (60.0% vs 61.5%) 
[41]. Efficacy data for the use of monotherapy polymyxins for 
MDR A. baumannii remain scarce with contrasting outcomes. 
Irrespective of the preceding limitations, polymyxins remain 
as a primary treatment option for MDR A. baumannii with the 
majority of clinical data surrounding polymyxins as combination 
therapy.
Minocycline 
Minocycline is yet another agent with a recent resurgence due to 
carbapenem- resistant Gram-negative infections, most notably 
CRAB. Following a brief hiatus, intravenous minocycline 
was re-introduced to the market in 2009 and is accompanied 
with an FDA-approved indication for infections caused by 
Acinetobacter spp. In vitro data suggests minocycline may 
play a role in the treatment of infections involving prosthetic 
material. In one study, minocycline prevented biofilm formation 
in 96% of biofilm-forming A. baumannii isolates [42]. In vitro 
susceptibility of A. baumannii to minocycline ranges from 70.3% 
to 79.1% in highly carbapenem-resistant isolates (meropenem 
susceptibilities ranging from 8.7% to 36.4%) [16,43,44]. In 
contrast, only 37.8% of 200 carbapenem-resistant isolates 
were minocycline susceptible in one report [45]. The majority 
of minocycline resistance (71.1%) in  A.  baumannii was due to 
the presence of the tet(B) clinical strains, whereas when this 
efflux pump was absent, only 6.7% of isolates were resistant 
[18]. Clinical success rates in CRAB VAP patients treated with 
minocycline are high (> 80%), yet clinical data are extremely 
limited and generally associated with combination therapy [46].
Tigecycline 
Tigecycline, a glycylcycline, is a semisynthetic derivative 
of minocycline that is able to overcome most tetracycline 
resistance mechanisms. Pharmacokinetic limitations, risk of 
treatment-emergent failure, and higher mortality (compared 
to imipenem-cilastatin) in HAP/VAP treated patients limit 
its widespread use [11,47]. Currently, no Clinical Laboratory 
Standards Institute (CLSI)-approved breakpoints for tigecycline 
against A. baumannii exist, and (as expected) variability 
in  testing  methods  have  produced  inconsistent  in  vitro 
susceptibility  results [48,49]. Although worldwide surveillance 
studies show that the MIC90 against MDR A. baumannii isolates 
has remained at 2 μg/mL, treatment-emergent resistance has 
occurred in various case reports at standard dosing [44,50] . 
This is thought to be a result of suboptimal concentrations of 
tigecycline (notably in the treatment of bacteremia) combined 
with overexpression of efflux pumps [20,32,50]. Clinical data 
concerning tigecycline treatment, often in combination, are 
not promising as higher rates of in-hospital mortality were 
observed [51]. Due to these limitations, tigecycline’s current 
role is generally restricted to the treatment of colistin-resistant 
isolates or as part of combination therapy to prevent the 
emergence of colistin resistance or heteroresistance.
Amikacin 
The emergence of resistance to all aminoglycosides is due 
to the production of aminoglycoside-modifying enzymes or 
efflux pumps mechanisms in MDR A. baumannii strains [11]. 
Amikacin is an aminoglycoside used in the treatment of A. 
baumannii infections since it often retains in vitro susceptibility 
to CRAB isolates. However, resistance rates to amikacin have 
been on the rise [27]. In one report, less than 20% of CRAB 
isolates maintained susceptibility to amikacin [52]. Treatment-
emergent resistance to amikacin has also been shown to 
develop [53]. Clinical studies evaluating amikacin monotherapy 
against A. baumannii infections are lacking.
Sulbactam-containing regimens
Sulbactam, a class A β-lactamase inhibitor, has intrinsic in 
vitro activity against A. baumannii and exhibits high-affinity 
for penicillin-binding proteins (notably types 1a and 2) [54]. 
However, resistance to sulbactam-containing combinations 
(such as ampicillin or cefoperazone) has dramatically increased 
with MICs often > 16 μg/mL. One study reports ampicillin-
sulbactam resistance rates at 72.3% in the years 2011-
2016 [27]. In  another report, rates of ampicillin/sulbactam 
susceptibility to carbapenem-susceptible strains was 94.1%, yet 
when tested against the carbapenem-resistant phenotype, only 
19.4% remained susceptible [45].
For these reasons, the majority of sulbactam-containing studies 
in the treatment of A. baumannii have been in combination with 
other therapies. In a pooled analysis of 13 studies, including one 
prospective study, sulbactam-containing combination regimens 
were similar in terms of clinical response, bacteriological 
response and in-hospital mortality compared to the control 
group. When analyzing for dose, the high-dose regimen 
(sulbactam > 9 g/day) was found to be more effective and was 
well tolerated without serious adverse effects [55]. High-dose 
sulbactam- containing regimens may be a suitable treatment 
option for CRAB at an MIC ≤ 4 μg/mL to preserve other 
therapies and better safety profile.
Combination Therapies
The vast majority of data surrounding combination therapies 
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Table 1. In vitro activity of select therapies against carbapenem-resistant A. baumannii isolates









Eravacycline 286 0.5 1 < 0.06 to > 64 [82]
707 1 2 0.06 to 8 [158]
52 0.5 2 < 0.016 to 4 [159]
193 1 2 0.12 to 8 [119]
Cefiderocol 595 (EU) 0.12 1 0.004 to 64 [101]
173 (NA) 0.25 1 < 0.002 to 8 [101]
562 0.5 2 < 0.002 to > 256 [102]
100 0.5 8 0.06 to > 64 [103]
768 0.12 1 < 0.002 to 64 [104]
107 0.06 0.5 < 0.03 to 2 [105]
44 0.12 1 0.012 to 4 [160]
ETX2514SUL 731 1 4 < 0.06 to 32 [54]
72 1 2 N/A [109]
TP-6076 121 0.03 0.06 < 0.002 to 0.12 [117]
326 0.06 0.125 0.008 to 0.5 [119]
41 0.008 0.063 0.002 to 0.25 [108]
EU: Europe; NA: North America; MIC50: minimum inhibitory concentration at which 50% of isolates are inhibited; MIC90: minimum inhibitory concentration 
at which 90% of isolates are inhibited; CRAB: carbapenem-resistant Acinetobacter baumannii
Table 2. In vitro susceptibility testing of select therapies for A. baumannii isolates [34].




Colistin < 2 > 4 •	 BMD is only approved MIC testing method; disk diffusion 
and gradient diffusion methods should not be performed
•	 Predicts MIC to polymyxin B
Minocycline < 4 8 > 16 •	 A. baumannii that are susceptible to tetracycline predicts 
susceptibility to minocycline. If intermediate/resistant to 
tetracycline, susceptibility to minocycline cannot be assured
Tigecycline - - -
Amikacin < 16 32 > 64
Ampicillin/sulbactam < 8/4 16/8 > 32/16
Meropenem < 2 4 > 8 •	 Breakpoints are based on a dosage regimen of 1 g adminis-
tered every 8 h or 500 mg administered every 6 h
Eravacycline - - -
Omadacycline - - -
Cefiderocol < 4 8 > 16 •	 Breakpoints based on a dosage regimen of2 g every 8 h 
administered over 3 h
•	 Testing cefiderocol required iron-depleted cation-adjusted 
Mueller-Hinton broth (CAMHB). Chelation is used for iron 
depletion, which removes other cations (calcium, magne-
sium, and zinc). Following this process, cations are added 
back to concentrations of calcium 20-25 mg/L, magnesium 
10-12.5 mg/L, and zinc 0.5-1.0 mg/L
MIC: minimum inhibitory concentration; S: susceptible; I: intermediate; R: resistant; BMD: broth microdilution
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of A. baumannii treatment are in patients with pneumonia 
or mixed infections. Polymyxin-based therapies were most 
commonly studied (> 50%), while tigecycline-based therapies 
were the next most frequent (25%) [34].
Several in vitro studies have shown synergistic effects of colistin 
in combination with sulbactam, tigecycline, carbapenems, 
glycopeptides, and others [56]. In addition, combination 
regimens may improve microbiological cure rates (when 
compared to monotherapy), yet has rarely translated to 
improved clinical outcomes, specifically reductions in mortality 
[57]. To date, five prospective trials have evaluated colistin-
based regimens combined with rifampin, fosfomycin (twice), 
ampicillin- sulbactam, and meropenem for MDR Gram-
negative bacteria, primarily A. baumannii [58-62]. When these 
data are combined, colistin combination therapy showed 
no difference for in-hospital morality and clinical response. 
Only the combination with ampicillin/sulbactam (n=39) was 
associated with a favorable clinical response compared to 
colistin monotherapy, whereas the remaining studies showed 
no difference for in-hospital mortality and clinical response 
[60,63]. While polymyxin-based therapies appear to offer 
no additional benefit over monotherapy groups, significant 
limitations to the available data remain. These include high 
mortality or treatment failure regardless of treatment, 
documentation of time to appropriate therapy, use of colistin 
rather than polymyxin B in invasive infections, and suboptimal 
reporting of MICs, dosing regimens, and use of concomitant 
antibiotics [30].
The majority of data for tigecycline-based combination therapies 
are limited to retrospective data in pneumonia treated patients, 
mainly VAP, and clinical outcomes are not promising. In two 
retrospective studies evaluating tigecycline monotherapy (100 
mg IV loading dose, then 50 mg IV  q12h)  versus  tigecycline-
based  combination  therapy  (multiple  agents),  there  was 
no difference in clinical success, mortality, or microbiological 
outcomes [64,65]. Similarly, when evaluating tigecycline-based 
combination therapy versus non-tigecycline-based combination 
therapy, clinical cure and mortality outcomes were similar 
[66-69], while microbiological eradication with tigecycline-
based therapy was significantly lower in one trial [67]. In a 
more recent evaluation of 238 adult ICU patients with CRAB 
pneumonia, those treated with tigecycline-based combination 
therapies had higher ICU mortality than non-tigecycline 
therapy (adjusted odds ratio 2.30, 95% confidence interval 
1.19-4.46) [70]. When the data are combined, treatment with 
tigecycline for MDR A. baumannii is associated with higher 
in-hospital mortality and trended towards a longer hospital 
stay; however, monotherapy versus combination therapies 
did not show the same difference [51]. While the data for 
tigecycline-combination therapies has obvious limitations, 
there seems to be no additional benefit of combination therapy 
with tigecycline. 
Data regarding use of minocycline combination are also 
sparse. A retrospective review of 36 VAP patients with CRAB 
isolates and treated with minocycline/doxycycline found a 
clinical response rate of 81.8% (n=11) for the monotherapy group 
and 80.0% (n=25) in those receiving minocycline-combination 
therapy [46]. Another retrospective review demonstrated 
a  clinical success rate of 40/55 (73%) in patients treated 
with minocycline for MDR A. baumannii infection of various 
types. Of those 55 patients, only three received treatment with 
minocycline monotherapy while 52 received combination with 
another active agent [71]. While doses utilized in these studies 
ranged from 200-400 mg daily, one study suggests utilizing 
high dose minocycline (e.g. 700 mg daily) or as combination 
therapy to prevent rapid emergence of  resistance [5]. However, 
the safety and tolerability of such regimens has not been 
established.
Pharmacokinetic / Pharmacodynamic 
(PK/PD)-Based Dosing
With the rising of resistance rates of A. baumannii and the 
lack of new antimicrobials to the marketplace in recent years, 
clinicians have pursued optimizing the dosing of existing agents 
based on their PK/PD properties. This includes utilizing higher 
doses, shortening the dosing interval and prolonging infusion 
times. Each of these principles may be applied to β-lactams 
(eg, carbapenems, ampicillin/sulbactam) as they demonstrate 
a time-dependent antibacterial activity with maximal 
bactericidal effects occurring at serum concentrations 
approximately four times the MIC of the pathogen for at least 
40% of the dosing interval [72]. Additionally, greater clinical 
cure and bacteriological eradication is achieved if the free drug 
concentration remains above the MIC of the pathogen for 100% 
of the dosing interval in critically ill patients [73].
While high-quality efficacy data are limited with this 
approach, β-lactam agents are generally well tolerated without 
an increased risk of toxicity when intermittent infusions were 
compared to prolonged infusion strategies. In the largest 
of these randomized control trials (all pathogens n=214, 
Acinetobacter spp. n=20), continuous infusion meropenem 
had a similar clinical cure rate when  compared  to  intermittent 
dosing [74]. Higher microbiological success  rates, shorter ICU 
lengths of stay, and shorter durations of meropenem therapy 
were observed with no difference in safety outcomes. In a 
meta-analysis comparing prolonged infusions to intermittent 
bolus doses of meropenem, the prolonged infusion cohort 
had higher rates of clinical success (OR 2.10, 95% CI 1.31-
3.38) and lower mortality (RR 0.66, 95% CI, 0.50-0.88) [75]. 
In the single study evaluating 30 HAP patients with MDR A. 
baumannii isolates, no difference in clinical efficacy or relapse 
rates were observed among cohorts [76]. Of note, doripenem 
is the lone carbapenem that should not utilize prolonged 
infusions, as higher mortality rates were seen among patients 
with microbiologically confirmed late-onset VAP [77].
To overcome suboptimal tigecycline concentrations, a phase 
II study and a retrospective analysis demonstrated higher 
tigecycline doses (100 mg IV every 12 hr) in VAP-treated 
patients were associated with improved clinical cure rates 
compared to standard doses without increases in adverse 
events [78,79]. While higher doses may be warranted in severe 
infections (eg, pneumonia), clinical data are limited due to early 
termination of the phase II study due to poor recruitment.
Newly Approved Therapies
Eravacycline 
Eravacycline (Xerava™) is a novel, fully synthetic fluorocycline 
antibiotic approved by the FDA in August 2018. Similar to 
other tetracycline derivatives, it inhibits bacterial protein 
synthesis by binding to the 30S ribosomal subunit [80]. 
Eravacycline is structurally similar to tigecycline, except it has 
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two modifications to the D-ring core at C-7 and C-9 [80]. These 
modifications enhance its antibacterial spectrum of activity and 
its stability against tetracycline- specific resistance mechanisms 
(e.g. efflux pumps and ribosomal protection proteins) [81].
Eravacycline demonstrates a broad spectrum of activity in 
vitro against aerobic and anaerobic Gram-positive and Gram-
negative pathogens, including MDR A. baumannii [80,82-
84]. The MIC50/90 were 0.06/0.5 μg/mL and 0.5/1 μg/
mL(respectively) against A. baumannii isolates from patients 
in 13 Canadian hospitals and 11 hospitals in New York 
[81,84]. Another study reported MIC50/90 values against 
CRAB isolates of 0.5 μg/mL and 1 μg/mL, respectively (Table 
1) [82]. In two in vitro studies, 89% and 96% of CRAB isolates 
had eravacycline MICs of ≤ 1 μg/mL [82,83]. When compared 
to tigecycline, eravacycline has been shown to be two- to four-
fold more potent than tigecycline against A. baumannii isolates, 
including carbapenem-resistant isolates [81-84].
The efficacy of eravacycline has been evaluated in several Phase 
II and III studies for the management of cIAI and cUTIs [85-88]. 
Despite these numerous studies, efficacy relating to infections 
caused by A. baumannii is limited. In a pooled analysis of the 
IGNITE 1 and 4 studies, the clinical and microbiological response 
rates were 100% for patients with A. baumannii, including 
MDR isolates [89]. Of note, IGNITE 1 only had 8 patients and 
IGNITE 4 had 5 patients with A. baumannii infections [85,90]. 
In contrast, the efficacy of eravacycline in cUTIs has not been as 
promising [88,91]. Eravacycline is eliminated predominately in 
the feces (with low urinary excretion), suggesting eravacycline 
may not be an effective treatment option for UTIs caused by 
MDR A. baumannii.
Eravacycline has been well-tolerated in clinical studies and 
most adverse events have been similar to comparator agents 
with a few exceptions. Notably, the reported incidences of 
infusion site reactions, nausea, and vomiting have been higher 
compared to carbapenems [80]. Despite higher incidences of 
nausea and vomiting compared to carbapenems, they are still 
significantly lower than those reported with tigecycline (6.5% 
vs 26% and 3.7% and 18%, respectively) [44,80]. One potential 
disadvantage of eravacycline compared to other therapies 
for MDR A. baumannii is the concern for drug interactions. 
Eravacycline is a substrate for the CYP450 enzyme system, 
specifically CYP3A. When administered concomitantly with a 
strong CYP3A inducer (e.g. rifampin), the dose of eravacycline 
should be increased to 1.5 mg/kg IV every 12 hours. There 
are no formal recommendations regarding eravacycline and 
strong CYP3A inhibitors at this time. Additionally, eravacycline 
has the potential to increase the effects of warfarin, thus dose 
adjustments may be warranted [80].
Omadacycline 
Omadacycline (NUZYRA™) is a semisynthetic derivative of 
minocycline and is a novel aminomethylcycline antibiotic. Much 
like eravacycline, omadacycline has the ability to remain active 
in the presence of tetracycline efflux and ribosomal protection 
genes resulting in a broad spectrum of activity [92].
In vitro omadacycline data against a collection of 2101 
worldwide clinical isolates of A. baumannii demonstrated an 
MIC50/90 of 2 μg/mL and 4 μg/mL, respectively, with 91.5% of 
isolates inhibited at MIC values < 4 μg/mL [92]. In a collection 
of 441 A. baumannii isolates from 2016, omadacycline 
MIC50/90 values were slightly higher at 4 μg/mL and 8 μg/mL, 
respectively, while 71.2% of isolates were inhibited at an MIC 
of < 4 μg/mL. Additionally, in the 293 tetracycline resistance 
strains, the MIC50/90 values were unchanged, although only 
57.3% of strains were inhibited at 4 μg/mL [93].
Omadacycline was granted FDA approval in October 2018 for 
the treatment of community-acquired  bacterial  pneumonia 
(CABP)  and  ABSSSI [73]. In  two  randomized  controlled 
trials, OPTIC and OASIS-1, treatment with omadacycline 
was noninferior for early clinical response when compared to 
moxifloxacin and linezolid, respectively [94,95]. However, 
both trials failed to include MDR Gram-negative pathogens, 
including A. baumannii. While studies are nearing 
completion for cystitis and pyelonephritis, it is unlikely that 
these will provide any useful data to its clinical utility in the 
treatment of A. baumannii.
Agents Undergoing Phase I-III Clinical 
Trials in the US
Cefiderocol 
Cefiderocol (previously S-649266) is a parenteral siderophore 
cephalosporin currently in phase III clinical trials for the 
treatment of nosocomial pneumonia and other severe infections 
caused by Gram-negative pathogens [96,97]. Cefiderocol has 
a unique catechol moiety at the C-3 position contributing 
to its mechanism of action, ability to chelate with ferric iron, 
and ultimately  bacterial  cell  entry.  Termed  a  “Trojan 
horse”  antibiotic  through  a  strategy  of exploiting the iron 
transport mechanism of bacteria, the siderophore-drug 
complex selectively interacts with the siderophore receptors 
on the bacterial cell surface to be actively transported across 
the  outer  membrane.  Due  to  this  mechanism,  this  novel 
antimicrobial  is  able  to circumvent permeability-mediated 
drug resistance [98,99]. The halogenated catechol group 
along with the quaternary amine at the C-3 position produces 
increased in vitro activity when certain MBLs, KPC and OXA 
producing strains are present [100].
Cefiderocol demonstrates potent in vitro activity in isolates 
tested against a broad range of ESBL-producing Gram-
negative organisms, including MDR and XDR P. aeruginosa 
and A. baumannii (susceptible breakpoint of 4 μg/mL, see 
Table 2), with negligible activity against Gram-positive aerobic 
and anaerobic bacteria [98]. When tested against 1148 A. 
baumannii isolates from North America and Europe, the MIC90 
value for cefiderocol was 1 μg/mL. When evaluated against 
CRAB, cefiderocol retained an MIC90 of 1 μg/mL and 96.9% 
(744/768) of meropenem-nonsusceptible isolates had MICs of 
< 4 μg/mL [101]. Other studies confirmed this potent activity 
against CRAB isolates ranging from 88% to 96.9% with MICs 
of < 4 μg/mL [102-104]. With regard to colistin-nonsusceptible 
strains of A. baumannii (n=121), cefiderocol’s MIC range was  < 
0.002 to 8 μg/mL with an MIC90  of 2 μg/mL [101].
 In another 
study comparing colistin-resistant strains versus  colistin  non-
resistant  strains,  the  MIC  range  of  cefiderocol  did  not  differ 
[105]. When evaluating specific carbapenemase enzymes, there 
does not appear to be a correlation of carbapenemase production 
and cefiderocol resistance [104]. Of note, the mechanisms 
conferring elevated MICs are currently being evaluated [104].
Cefiderocol has been well tolerated in phase I and II studies with 
its safety profile being similar to that of other cephalosporins 
[106,107]. Most adverse events have been gastrointestinal 
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related (diarrhea, constipation, nausea, vomiting) while 
occurring less frequently than the comparator agent (12% 
vs 18%, respectively) [107]. Cefiderocol is a β-lactam with a 
chemical structure most closely related to cefepime. Allergic 
reactions are possible, however, only one patient discontinued 
treatment due to urticaria during the infusion. This adverse 
event was deemed not to be an antibody-mediated reaction 
[106].
To date, the efficacy of cefiderocol has been evaluated in 
one completed Phase II trial. This study included 452 patients 
for the treatment of cUTI at risk for MDR Gram-negative 
uropathogens, primarily E. coli and K. pneumoniae (no A. 
baumannii isolates noted), compared to high-dose imipenem-
cilastatin. Cefiderocol met the noninferiority primary endpoint 
of the composite of clinical and microbiological outcomes at the 
test-of-cure (73% vs 55%, p=0.0004) and achieved superiority 
in the post-hoc analysis [107].
Two phase III clinical trials focusing on the treatment of invasive 
MDR pathogens are currently enrolling patients [96,97]. The 
CREDIBLE-CR trial (NCT02714595) is estimated to enroll 
150 patients to compare cefiderocol to best available therapy 
(a polymyxin-based or non-polymyxin based regimen) for the 
treatment of severe infections (BSI, HAP/VAP, cUTI, sepsis) 
caused by CR Gram-negative pathogens [96]. The APEKS-NP 
trial (NCT03032380), is estimated to enroll approximately 300 
patients to compare 14-day all-cause mortality with cefiderocol 
versus meropenem (both in association with linezolid) in adults 
for the treatment of nosocomial pneumonia caused by Gram-
negative pathogens [97].
ETX2514 + sulbactam (ETX2514SUL) 
ETX2514, a novel diazabicyclooctane β-lactamase inhibitor, 
also has intrinsic activity to Enterobacteriaceae and also 
has the ability to fully restore sulbactam’s activity against 
A. baumannii while protecting against all serine-dependent 
β- lactamases (Class A, C, and D) [108]. In a globally diverse 
collection of A. baumannii isolates (n=1131), the in vitro activity 
of ETX2514SUL was 16-fold more active than sulbactam alone 
(MIC90 4 μg/mL vs 64 μg/mL, respectively) [54]. Additionally, 
ETX2514SUL retained the same activity when subsets of 
meropenem-resistant (Table 1), colistin-resistant, and MDR 
isolates were evaluated, while there was reduced  activity 
against one isolate containing an  MBL [54]. Similarly, a 
study of 72 A. baumannii isolates with the majority being 
MDR isolates, had an MIC90 of 2 μg/mL [109]. Spontaneous 
resistance has not been observed and the use of this agent 
has not resulted in the generation of resistant β-lactamases to 
ETX2514SUL [110].
One phase II study has been completed with positive results 
[111]. This phase II double-blind, placebo-controlled trial of 
80 patients compared ETX2514SUL (1g/1g q6h for 7 days) 
plus imipenem-cilastatin to imipenem-cilastatin plus placebo 
in adult patients with cUTI including acute pyelonephritis. 
Outcomes were similar between the two groups. In an 
exploratory analysis, eight patients had imipenem-non-
susceptible pathogen resulting in microbiological eradication 
in 3/3 (100%) in the ETX2514SUL plus imipenem-cilastatin 
cohort vs 3/5 (60%) patients in the imipenem-cilastatin plus 
placebo cohort. Entasis Therapeutics plans to initiate a Phase 
III study focused on CRAB infections in the first quarter of 2019 
[111].
TP-271 
TP-271 is a novel, fully-synthetic fluorocycline antibiotic under 
the development by Tetraphase Pharmaceuticals for treatment 
of CABP, pneumonic tularemia, and other serious respiratory 
bacterial/bio threat infections [112,113]. When the most 
common tetracycline-specific mechanisms are present, efflux 
pumps and ribosomal protection proteins, TP271 remains 
active in vitro [114]. When evaluated against four CRAB 
isolates in a neutropenic lung mouse model, TP271 was dose-
dependent with area under the curve (AUC) to MIC ratio best 
correlating with efficacy.  This  study  supported  the  future 
research  in  respiratory  infections  including  A. baumannii 
infections. A phase I study of escalating doses was well tolerated 
with gastrointestinal symptoms being most frequently reported 
[112]. Additionally, there are two ongoing phase I studies 
assessing single and multiple ascending doses of an oral 
formulation [115,116].
TP-6076 
Another novel, fully synthetic tetracycline is currently 
in phase I studies. It has a similar mechanism of action to 
tetracyclines in which it disrupts bacterial synthesis by binding 
to the 30S ribosomal subunit. In vitro data have shown potent 
activity against CRAB isolates with many containing OXA and 
OXA-like β-lactamases [117-120]. In the largest of these studies 
with 326 global isolates from the years 2005-2016, TP-6076 
had MIC50 and MIC90 values of 0.06 μg/mL and 0.125 μg/
mL while eravacycline had values of 0.5 μg/mL and 1 μg/mL, 
respectively (Table 1) [119]. TP-6076 did not demonstrate 
higher MIC values when comparing colistin-susceptible and 
non-susceptible isolates. However, the MIC90 was one dilution 
lower for tigecycline- and minocycline-susceptible and non-
susceptible isolates [117]. In isolates overexpressing genes 
encoding the AdeABC multidrug efflux pump, the major 
contributor to tigecycline resistance, TP-6076 had an MIC 
range of 0.008 to 0.13 μg/mL [118]. Gastrointestinal events 
(nausea and vomiting)  were  the  most  frequently reported 
adverse  event  with  higher  rates  at  the  higher doses [121]. A 
second   phase   I   study   is   currently   recruiting   to   assess 
the   safety   and bronchopulmonary PK with a dose of 30 mg 
daily [122]. With very little data, it seems as if TP-6076 is 
minimally impacted by the major resistance mechanisms of 
the tetracycline class with MICs mostly unaffected by serine-
dependent β-lactamases.
VNRX-5133 + cefepime 
Combined with cefepime, VNRX-5133 is a cyclic boronate 
β- lactamase inhibitor with broad-spectrum activity against 
serine- (classes A, C, and D) and metallo-β-lactamases (VIM/
NDM, class B). This combination agent is primarily being 
explored for CRE and CR Pseudomonas aeruginosa. In vitro 
data describes VNRX-5133/cefepime as a highly active agent 
against Enterobacteriaceae and P. aeruginosa that is resistant 
or has evolved resistance to other β-lactam/ β-lactamase 
inhibitors, however, its use against A. baumannii has not been 
described [123].
Zidebactam  (WCK  5107),  WCK  5153,  cefepime/zidebactam  
(WCK  5222)  
Zidebactam (WCK  5107)  and  WCK5153  are  novel  non-β-
lactamase  bicyclo-acyl  hydrazide  β-lactam enhancer antibiotics 
that are under development for MDR Enterobacteriaceae, 
P. aeruginosa, and CRAB [124]. These novel agents have a 
dual mechanism of action where they enhance β- lactams 
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through complementary high-affinity binding to PBP2 while 
strongly inhibiting class A and C β-lactamases along with 
modest inhibition of Class D β-lactamases. When zidebactam 
is combined with cefepime (WCK 5222) in vitro against 5946 
Enterobacteriaceae isolates, the combination demonstrated 
potent activity even against CR isolates. However, the MIC 
range of 639 A. baumannii isolates was 0.06 μg/mL to > 64 
μg/mL with only 44.3% of isolates having a MIC < 8 μg/mL 
[125]. These are less than optimal in vitro results against A. 
baumannii isolates, yet in vivo activity against OXA-23 or OXA-
24 isolates in a neutropenic thigh model and lung infection 
model showed greater than expected results [110,126].
WCK 5222 has been well tolerated in Phase I studies in subjects 
with both normal and impaired renal dysfunction [127,128]. 
Both agents are highly renally eliminated and will require dose 
adjustments based on the severity of dysfunction [127]. The 
pharmacodynamic property predicting therapeutic response for 
WCK 5222 is the free drug concentration in plasma exceeding 
the MIC over the dosing interval (Tf   > MIC). In subjects with 
normal renal function receiving multiple doses  of  either  2  g/1 
g  or  2  g/2  g  of  cefepime/zidebactam,  AUC  and  maximum 
serum concentration  (Cmax)  were  dose  proportional,  no 
accumulation  occurred,  and  no pharmacokinetic interaction 
was observed when co-administered [128]. Phase I studies 
evaluating plasma and lung tissue provided data to support the 
use of WCK 5222 in the treatment of pneumonia, while other 
organ systems have yet to be evaluated [129].
Other Antibiotics
AIC-499 (BL) + unknown BLI 
AIC499 is termed as an innovative β-lactam antibiotic and is 
combined with a currently unspecified β-lactamase inhibitor. 
According to the drug developer’s website, AIC499 shows 
potent activity against many Gram-negative pathogens 
including MDR P. aeruginosa and A. baumannii for use in 
cUTI and cIAI. Phase I studies were expecting results in 2017 
with plans for future phase II studies, however, no trials are 
currently registered on multiple government trial registries. 
The phase I study was to be a single dose study in 48 
healthy subjects immediately followed by a multiple ascending 
dose study in 36 subjects at the Medical   University   of   Vienna, 
Austria.   The   Innovative   Medicines   Initiative   with   the 
COMBACTE-MAGNET project is supporting AiCuris in the 
clinical development of AIC499 [130].
GSK3342830 (GSK830) 
GSK3342830 or GSK830 is a catechol-cephalosporin with a 
spectrum of activity similar to that of the other siderophore 
cephalosporin, cefiderocol [131]. In vitro data are promising 
against A. baumannii with 94 MDR global isolates having 
MIC50 and MIC90  of 0.06 μg/mL and 0.6 μg/mL, respectively 
[131]. However, a phase I dose-escalation study was stopped 
early. It is important to note that 35.7% of subjects discontinued 
the study drug during the multi- dose arm due to fever, 
headache, malaise or transaminitis [132].
SPR741 (formerly NAB74) 
SPR741 (formerly NAB74) is a polymyxin-B-like molecule 
being developed as an antibiotic adjuvant for the treatment 
of XDR A. baumannii. This molecule does not have certain 
structural features of the polymyxins that contribute to their 
nephrotoxicity, however, this agent has minimal intrinsic 
activity against A. baumannii and must be used as combination 
therapy [133]. When  combined  with  rifampin  in  pre-clinical 
data  of  a  murine pneumonia model, this combination has 
shown to be effective in reducing bacterial burden (suggesting 
utility in A. baumannii lung infections) [133,134]. SPR741 has 
a short half-life of approximately 3 hours with 50% of the drug 
excreted in the urine within one-hour post-dose with no evidence 
of accumulation with 400 mg administered intravenously 
every 8 hours [135]. Other phase I studies have been completed 
in 2017; however, no results are available [136,137].
Novel Therapies
Monoclonal antibodies 
Antibacterial monoclonal antibodies (MAbs) have the ability 
to protect (e.g., palivizumab for prophylaxis against respiratory 
syncytial virus) and treat (e.g., obiltoxaximab for treatment 
of inhalational anthrax) against deadly infections. MAbs 
are highly specific and may lessen the disruption of normal 
gastrointestinal flora with less selective pressure for cross- 
resistance with antibiotics [138]. Additionally, antibacterial 
MAbs could have an enormous impact on controlling 
institutional outbreaks once the pathogen is known. However, 
aside from their narrow spectrum, there are concerns 
surrounding the use of MAb therapy in infectious diseases. 
Notably, these include high cost, complex administration, and 
barriers to MAb development [139].
Several studies have shown MAb efficacy against A. baumannii 
in mice when provided as active immunization (i.e., vaccine) 
and passive immunization in various models [140-143]. Most 
recently, a MAb, C8 in an A. baumannii mice pneumonia and 
sepsis model demonstrated enhanced bacterial clearance, 
prevented progression to septic shock, and had synergistic 
activity with colistin. An area of concern in this study was the 
ability of C8 to bind to only 60% of A. baumannii strains tested 
[144].
Phage therapy 
As A. baumannii resistance continues to increase and the 
portfolio of antibiotics is becoming increasingly less effective, 
bacteriophage therapy becomes an alluring option. Termed 
“phage,” this technology is simply a virus engineered to infect a 
pathogenic bacterium, replicate inside the host cell, and finally 
rupture the bacterial cell wall resulting in cell death [145]. 
Similarly to  MAbs,  phage  are  highly  specific,  infecting  only 
prokaryotic  cells  resulting  in minimal toxicities and side effects 
[146]. Additionally, their mechanism of action is completely 
independent of antibiotics so their efficacy is not altered 
against highly resistant bacteria [147]. Other advantages of 
this technology include the potential for combinations with 
traditional therapies [148]. However, numerous questions about 
this therapy remain. This therapy is not currently recognized as 
a drug and a clear lack of regulatory framework exists [145,149]. 
Because it is given in high quantities, the human body may 
recognize phage as foreign antigens, produce antibodies, 
and theoretically result in a diminished activity. Finally, the 
possibility of horizontal gene transfer can occur resulting in 
the transfer of resistance genes and virulence factors between 
bacterium and phage [146].
Numerous studies (n=30) with a total of 1,152 patients have been 
conducted to evaluate the efficacy and safety of phage therapy 
against ESKAPE pathogens. Of the 30 studies, 87% showed 
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efficacy of reducing bacterial growth with successful outcomes. 
Twenty-two studies reported on the safety profile with only two 
reporting side effects after phage treatment [147]. Regarding 
A. baumannii specific infections, several animal models have 
been conducted in MDR and CRAB isolates with promising 
results [150-155]. To date, only two human case reports of 
phage therapy directed against MDR A. baumannii have been 
published [156,157]. The first describes a case of a 68-year-old 
diabetic patient with necrotizing pancreatitis complicated by an 
MDR A. baumannii infection. In conjunction with combination 
antibiotics, three phage cocktails were provided intravenously 
and percutaneously into the abscessed cavity in repeated daily 
intervals for a total of 59 days. The patient’s initial status was 
improved after commencing phage therapy with an eventual 
return to health. Interestingly, however, subsequent cultures 
were obtained with strains showing reduced susceptibility to 
phage therapy [157]. The second case report describes a 77-
year- old traumatic brain injury patient undergoing craniectomy 
complicated by cerebritis and subdural and epidural empyemas. 
Debridement was deemed necessary and intraoperative 
cultures grew MDR A. baumannii. In addition to antibiotics, 
the first dose of phage therapy was administered intravenously 
on day 12 and continued for 8 days (98 intravenous 
administrations). While the site of infection healed, the patient 
did not clinically improve and family withdrew care on hospital 
day 19 [156].
Conclusion
Acinetobacter  baumannii  has  the  extraordinary  adaptive 
ability  to  develop  resistance  to overcome all treatment 
options currently available. Despite the promising focus in 
recent years on developing novel therapies, more real-world 
experience in critically ill patients with invasive MDR A. 
baumannii infections is needed to solidify a place in therapy for 
one or more of these novel therapies. Moreover, many of these 
novel antimicrobials have already demonstrated vulnerability 
as reports of increasing MICs have been observed. Despite these 
challenges, novel treatment modalities for MDR A. baumannii 
are encouraging, yet further advances will be required as the era 
of antimicrobial resistance continues.
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